6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial
Helena Earl(University of Cambridge), Joanne Cliff, Jean Abraham(Cancer Research UK), Claire Hulme(University of Leeds), C. Bedi, Lisa Barraclough, David Miles(Guy's Hospital), Kim Benstead(Cheltenham General Hospital), Karen McAdam(Peterborough City Hospital), Ioannis Gounaris(Novartis (Switzerland)), Sanjay Raj(University Hospital Southampton NHS Foundation Trust), Janet Dunn(National Health Service), Kerry Raynes(University of Warwick), Susan Cleator(Imperial College Healthcare NHS Trust), Daniel Rea(University Hospitals Birmingham NHS Foundation Trust), C. Bale, U. Barthakur, Mei-Lin Ah-See(Mount Vernon Cancer Centre), Donna Howe(University of Warwick), Betania Mahler‐Araujo(National Health Service), Chris Plummer(Newcastle upon Tyne Hospitals NHS Foundation Trust), Helen Higgins(University of Warwick), Luke Hughes‐Davies(National Health Service), Peter S Hall(University of Edinburgh), David Bloomfield(Royal Sussex County Hospital), Rebecca Bowen, Chris Bradley(Institute of Health Economics), Jane Brown(University of Warwick), Anne Armstrong(The Christie NHS Foundation Trust), Mark Churn(Guy's and St Thomas' NHS Foundation Trust), Caroline Archer(Queen Alexandra Hospital), Anne-Laure Vallier(National Health Service), Roshan Agarwal(Imperial College Healthcare NHS Trust), R. Allerton, Andrew Wardley(UK Research and Innovation), Elena Provenzano(University of Cambridge), Hafiz Algurafi, Mark Harries(Guy's and St Thomas' NHS Foundation Trust), Pamela Woodings(Royal Derby Hospital), Carlos Caldas(University of Cambridge), Louise Hiller(University of Warwick), Christopher McCabe(University of Leeds), Shrushma Loi(University of Warwick), Anita Chhabra(National Health Service), Maggie Wilcox(University of Colorado Anschutz Medical Campus), Mohammad Butt, Janine Mansi(Guy's and St Thomas' NHS Foundation Trust), Richard Simcock(Royal Sussex County Hospital), Adrian Harnett(Norfolk and Norwich University Hospital), David Cameron(Corewell Health)
Cited by 287
Related Papers
Signatures of mutational processes in human cancer
|Nature|2013|10.1k
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k